USSN: 10/018,201

Attorney Docket No: 1059.00063

IN THE CLAIMS:

1. (Currently amended) A method of promoting neurogenesis neuron growth comprising the step of:

administering a therapeutic amount of a nitric oxide donor compound <u>selected</u> from the group consisting essentially of DETANONOate, PAPANONOate, S-nitroso-N-acetylpenicillamine, sodium nitroprusside, sodium nitroglycerine, phosphodiesterase <u>inhibitors and L-arginine</u> to a patient in need of neurogenesis neuron growth promotion post stroke.

- 2. (Currently Amended) A compound for promoting neurogenesis neuron growth comprising an effective amount of a nitric oxide donor sufficient to promote neurogenesis.
- 3. (Currently amended) A neurogenesis promoter comprising a nitric oxide donor <u>capable of promoting neuron growth</u> in a pharmaceutically acceptable carrier.
- 4. (Original) The neurogenesis promoter according to claim 3, wherein said nitric oxide donor augments nitric oxide in a tissue.
- 5. (Previously Presented) The neurogenesis promoter according to claim 4, wherein said nitric oxide donor is selected from the group consisting essentially of phosphodiesterase inhibitors and L-arginine.
- 6. (Original) A method of augmenting the production of neurons by administering an effective amount of a nitric oxide donor <u>selected from the group consisting essentially of DETANONOate, PAPANONOate, S-nitroso-N-acetylpenicillamine, sodium nitroprusside, sodium nitroglycerine, phosphodiesterase inhibitors and L-arginine to a site in need of augmentation.</u>

USSN: 10/018,201

Attorney Docket No: 1059.00063

7. (Currently amended) A method of increasing neurological function <u>via</u> <u>neuron growth</u> by administering an effective amount of a nitric oxide donor <u>selected</u> <u>from the group consisting essentially of DETANONOate, PAPANONOate, S-nitroso-N-acetylpenicillamine, sodium nitroprusside, sodium nitroglycerine, phosphodiesterase <u>inhibitors and L-arginine to promote neuron growth</u> to a patient in need of increased neurological function <u>after neurological damage has occurred to produce neuron growth</u>.</u>

8. (Currently amended) A method of increasing cognitive and neurological function via neuron growth by administering an effective amount of a nitric oxide donor compound selected from the group consisting essentially of DETANONOate, PAPANONOate, S-nitroso-N-acetylpenicillamine, sodium nitroprusside, sodium nitroglycerine, phosphodiesterase inhibitors and L-arginine to promote neuron growth to a patient in need of increased cognitive and neurological function after neurological and cognitive damage has occurred to produce neuron growth.